{"filing":{"accession_number":"0001628280-26-055477","cik":"0001567892","ticker":null,"company_name":"Keenova Therapeutics plc","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"mnk-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1567892/000162828026055477/mnk-20260811.htm"},"events":[{"id":26814,"run_id":24387,"accession_number":"0001628280-26-055477","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Keenova Therapeutics plc disclosed its financial results for the second quarter ended June 30, 2026, under Item 2.02, reporting net sales of $517 million from continuing operations, Acthar Gel net sales of $205 million (17% growth), XIAFLEX net sales of $150 million, and a loss from continuing operations of $221 million. The filing includes revised full-year 2026 guidance raising Acthar Gel growth to 20%-22% and tightening XIAFLEX guidance to high single-digits growth, along with pro forma net sales and Adjusted EBITDA guidance. This is a standard quarterly earnings release with material financial results and forward guidance.","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28076,"accession_number":"0001628280-26-055477","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Keenova Therapeutics plc disclosed its financial results for the second quarter ended June 30, 2026, under Item 2.02, reporting net sales of $517 million from continuing operations, Acthar Gel net sales of $205 million (17% growth), XIAFLEX net sales of $150 million, and a loss from continuing operations of $221 million. The filing includes revised full-year 2026 guidance raising Acthar Gel growth to 20%-22% and tightening XIAFLEX guidance to high single-digits growth, along with pro forma net sales and Adjusted EBITDA guidance. This is a standard quarterly earnings release with material financial results and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T10:36:07.829656+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28076,"accession_number":"0001628280-26-055477","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Keenova Therapeutics plc disclosed its financial results for the second quarter ended June 30, 2026, under Item 2.02, reporting net sales of $517 million from continuing operations, Acthar Gel net sales of $205 million (17% growth), XIAFLEX net sales of $150 million, and a loss from continuing operations of $221 million. The filing includes revised full-year 2026 guidance raising Acthar Gel growth to 20%-22% and tightening XIAFLEX guidance to high single-digits growth, along with pro forma net sales and Adjusted EBITDA guidance. This is a standard quarterly earnings release with material financial results and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T10:36:07.829656+00:00","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-08-11"}]}